Zobrazeno 1 - 10
of 58
pro vyhledávání: '"D. Falls"'
Publikováno v:
Journal of Limb Lengthening & Reconstruction, Vol 6, Iss 1, Pp 13-19 (2020)
Introduction: Distraction osteogenesis is an effective method for the treatment of congenital and acquired limb length discrepancy. Lengthening and then nailing (LATN) was developed to decrease the time in external fixation. With the advent of motori
Externí odkaz:
https://doaj.org/article/248c7b904782482a9fa36462b23922b8
Autor:
Edward B. Reilly, Neal C. Goodwin, Laura M. McKay, Fritz G. Buchanan, Jonathan A. Meulbroek, Dong Cheng, Peter J. DeVries, Hugh D. Falls, Suzanne Norvell, Michael J. Mitten, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Targeting tumor-overexpressed EGFR with an antibody–drug conjugate (ADC) is an attractive therapeutic strategy; however, normal tissue expression represents a significant toxicity risk. The anti-EGFR antibody ABT-806 targets a unique tumor-specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7af9a53ea623c6dab8499fd2219a76bc
https://doi.org/10.1158/1535-7163.c.6538540.v1
https://doi.org/10.1158/1535-7163.c.6538540.v1
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Diana Cao, Sherry L. Ralston, Lise I. Loberg, Sarah R. Mudd, David R. Reuter, Martin J. Voorbach, Kenneth R. Durbin, Fritz G. Buchanan, Sanjay C. Panchal, Jonathan A. Meulbroek, Chung-Ming Hsieh, Lorenzo Benatuil, Peter J. DeVries, Michael J. Mitten, Hugh D. Falls, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Amino Acid Sequence of AM-1 VH Region
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4690d3c6ba234726f181827c74d28b66
https://doi.org/10.1158/1535-7163.22505197
https://doi.org/10.1158/1535-7163.22505197
Autor:
Edward B. Reilly, Neal C. Goodwin, Laura M. McKay, Fritz G. Buchanan, Jonathan A. Meulbroek, Dong Cheng, Peter J. DeVries, Hugh D. Falls, Suzanne Norvell, Michael J. Mitten, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Table S1: Mouse Strains Used for Xenograft Studies; Table S2: ABT-414 Growth Inhibition of Xenograft Tumors; Figure S1: Efficacy of ABT-414, ABT-806-vcMMAE, and unconjugated MMAE co-dosed with ABT-806 in U87MGde2-7 Tumor-Bearing Mice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::161f204be3c985a50dfa14ac1e0540f9
https://doi.org/10.1158/1535-7163.22506979
https://doi.org/10.1158/1535-7163.22506979
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Diana Cao, Sherry L. Ralston, Lise I. Loberg, Sarah R. Mudd, David R. Reuter, Martin J. Voorbach, Kenneth R. Durbin, Fritz G. Buchanan, Sanjay C. Panchal, Jonathan A. Meulbroek, Chung-Ming Hsieh, Lorenzo Benatuil, Peter J. DeVries, Michael J. Mitten, Hugh D. Falls, Kedar S. Vaidya, Erwin R. Boghaert, Andrew C. Phillips
Depatuxizumab mafodotin (depatux-m, ABT-414) is a tumor-selective antibody drug conjugate (ADC) comprised of the anti-EGFR antibody ABT-806 and the monomethyl auristatin F (MMAF) warhead. Depatux-m has demonstrated promising clinical activity in glio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::313f2d242d9ae4aea09b4db055c77042
https://doi.org/10.1158/1535-7163.c.6537985.v1
https://doi.org/10.1158/1535-7163.c.6537985.v1
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Thomas John, Puey-Ling Chia, Diana Cao, Joann P. Palma, Wenqing Gao, Erwin R. Boghaert, Kedar S. Vaidya, Anatol Oleksijew, Michael J. Mitten, Hugh D. Falls, Mark G. Anderson
In vivo Efficacy of ABBV-321 tumor targeting.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::677c6299c1714e54b6ad5827987299cc
https://doi.org/10.1158/1535-7163.22518654
https://doi.org/10.1158/1535-7163.22518654
Autor:
Edward B. Reilly, Andrew M. Scott, Hui K. Gan, Thomas John, Puey-Ling Chia, Diana Cao, Joann P. Palma, Wenqing Gao, Erwin R. Boghaert, Kedar S. Vaidya, Anatol Oleksijew, Michael J. Mitten, Hugh D. Falls, Mark G. Anderson
ABBV-321 (serclutamab talirine), a next-generation EGFR-targeted antibody–drug conjugate (ADC) incorporates a potent pyrrolobenzodiazepine (PBD) dimer toxin conjugated to the EGFR-targeting ABT-806 affinity-matured AM1 antibody. ABBV-321 follows th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95d6b8106485307d7fd6d8f1fb1b654d
https://doi.org/10.1158/1535-7163.c.6542049
https://doi.org/10.1158/1535-7163.c.6542049
Autor:
Hugh D. Falls, Michael J. Mitten, Edward B. Reilly, Adelyn L Zelaya-Lazo, Erwin R. Boghaert, Anatol Oleksijew, Kedar S. Vaidya, Joann P. Palma, Sasmita Mishra, Cory Alvey, Peter Ansell, Mark Anderson, Andrew C. Phillips
Publikováno v:
Journal of Neuro-Oncology. 152:233-243
Purpose: Depatux-m is an antibody drug conjugate (ADC) that targets and inhibits growth of cancer cells overexpressing the epidermal growth factor receptor (EGFR) or the 2–7 deletion mutant (EGFRvIII) in tumor models in vitro and in vivo. Treatment
Autor:
Anatol Oleksijew, Thomas John, Diana Cao, Mark Anderson, Joann P. Palma, Kedar S. Vaidya, Puey-Ling Chia, Michael J. Mitten, Hugh D. Falls, Hui K Gan, Edward B. Reilly, Andrew M. Scott, Wenqing Gao, Erwin R. Boghaert
Publikováno v:
Molecular Cancer Therapeutics. 19:2117-2125
ABBV-321 (serclutamab talirine), a next-generation EGFR-targeted antibody–drug conjugate (ADC) incorporates a potent pyrrolobenzodiazepine (PBD) dimer toxin conjugated to the EGFR-targeting ABT-806 affinity-matured AM1 antibody. ABBV-321 follows th
Autor:
Kedar S, Vaidya, Michael J, Mitten, Adelyn L, Zelaya-Lazo, Anatol, Oleksijew, Cory, Alvey, Hugh D, Falls, Sasmita, Mishra, Joann, Palma, Peter, Ansell, Andrew C, Phillips, Edward B, Reilly, Mark, Anderson, Erwin R, Boghaert
Publikováno v:
Journal of neuro-oncology. 152(2)
Depatux-m is an antibody drug conjugate (ADC) that targets and inhibits growth of cancer cells overexpressing the epidermal growth factor receptor (EGFR) or the 2-7 deletion mutant (EGFRvIII) in tumor models in vitro and in vivo. Treatment of patient